A customer shops in a Kroger grocery store on July 15, 2022 in Houston, Texas. Brandon Bell | Getty Images Investors have cheered a new class of weight loss drugs for their ability to help people shed unwanted pounds, but the findings of a recent poll underscore the challenges patients face if they cease treatment. … Read more
Demand for the drugs is unlikely to slow down in 2024, especially as treatments gradually become more accessible. Much of Wall Street believes the weight loss drug market will only expand, with some analysts projecting that it will be worth $100 billion by the end of the decade. Goldman Sachs analysts expect 15 million U.S. adults … Read more
49 Mins Ago Europe stocks to open higher IG data shows European markets opening higher, with the FTSE 100 up 26 points at 7,473, France’s CAC 40 up 22 points at 7,085, and Germany’s DAX up 53 points at 15,197. — Jenni Reid 5 Hours Ago China services activity rebound slightly in October: Caixin survey … Read more
Blockbuster weight loss and diabetes drugs like Wegovy and Ozempic may be associated with an increased risk of three rare, but severe, stomach conditions in non-diabetic patients, according to a new study released Thursday. Researchers at the University of British Columbia said the risks include one condition not named in the warning labels for the … Read more
Scientists have begun investigating whether so-called miracle obesity drugs can be used to help treat conditions such as dementia and alcohol addiction. Recent trials have pointed to the drugs’ efficacy in curbing major cardiovascular events and reducing heart-failure related symptoms. The findings mark a milestone as pharmaceutical companies such as Novo Nordisk and Eli Lilly … Read more
4 Hours Ago Stocks open little changed The three major indexes were near flat at open. The Dow, S&P 500 and Nasdaq Composite were all within 0.1% of their flatlines shortly after 9:30 a.m. ET. — Alex Harring 5 Hours Ago British insurer Hiscox down 9% after weak retail outlook Hiscox was the worst performer … Read more
Novo Nordisk’s obesity drug Wegovy slashed the risk of serious heart problems by 20% in a large clinical trial. That landmark finding could put more pressure on U.S. insurers to cover the blockbuster medication and similar weight loss treatments. But organizations representing insurers emphasized that the data is still preliminary, and concerns remain about the … Read more
Popular weight-loss drug Wegovy could be made available under more health insurance schemes following the results of a late-stage trial, analysts said Wednesday. Novo Nordisk’s closely watched “SELECT” trial exceeded expectations Tuesday, indicating that Wegovy reduced the risk of major cardiovascular events such as heart attacks or strokes by 20%. “Data like this is going … Read more